First Midwest Bank Trust Division Has $3.06 Million Stake in Amgen, Inc. (AMGN)

First Midwest Bank Trust Division grew its position in Amgen, Inc. (NASDAQ:AMGN) by 5.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,385 shares of the medical research company’s stock after purchasing an additional 795 shares during the period. First Midwest Bank Trust Division’s holdings in Amgen were worth $3,055,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in AMGN. FMR LLC increased its holdings in Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after buying an additional 2,587,041 shares during the last quarter. Vanguard Group Inc. increased its holdings in Amgen by 0.9% during the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock worth $8,981,266,000 after buying an additional 489,720 shares during the last quarter. BlackRock Inc. increased its holdings in Amgen by 1.9% during the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after buying an additional 909,689 shares during the last quarter. Nordea Investment Management AB increased its holdings in Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after buying an additional 806,119 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Amgen by 3.1% during the second quarter. The Manufacturers Life Insurance Company now owns 3,968,892 shares of the medical research company’s stock worth $683,562,000 after buying an additional 121,202 shares during the last quarter. Institutional investors own 78.46% of the company’s stock.

In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The disclosure for this sale can be found here. Insiders sold 8,575 shares of company stock valued at $1,509,339 over the last 90 days. 0.19% of the stock is owned by company insiders.

A number of analysts recently issued reports on the stock. Mizuho set a $192.00 price objective on shares of Amgen and gave the stock a “buy” rating in a report on Friday, December 22nd. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Royal Bank of Canada decreased their price objective on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a report on Thursday, October 26th. Credit Suisse Group restated a “neutral” rating and set a $186.00 price objective (up previously from $177.00) on shares of Amgen in a report on Friday, September 29th. Finally, Oppenheimer restated a “buy” rating and set a $203.00 price objective on shares of Amgen in a report on Thursday, September 7th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $189.94.

Amgen, Inc. (NASDAQ AMGN) opened at $176.09 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72. Amgen, Inc. has a 1 year low of $145.62 and a 1 year high of $191.10. The company has a market cap of $127,830.00, a P/E ratio of 15.91, a PEG ratio of 2.55 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. During the same period last year, the business earned $3.02 earnings per share. Amgen’s revenue was down .7% compared to the same quarter last year. analysts predict that Amgen, Inc. will post 12.67 EPS for the current fiscal year.

Amgen announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its stock is undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a $1.32 dividend. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s dividend payout ratio (DPR) is 41.55%.

COPYRIGHT VIOLATION NOTICE: This article was published by Week Herald and is owned by of Week Herald. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://weekherald.com/2017/12/27/first-midwest-bank-trust-division-has-3-06-million-stake-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply